The information you are about to see is intended for U.S. healthcare professionals.
Please confirm you are a U.S. healthcare professional.
Consider how the first and
only oral therapy may help
For adults with confirmed Fabry disease and an amenable galactosidase alpha gene (GLA) variant associated with either the classic* or non-classic phenotype1,2
*
Defined as males with residual peripheral blood mononuclear cell alpha-galactosidase A (alpha-Gal A) <3% of normal and multiorgan system involvement.
Not an actual patient with Fabry disease.
Not an actual patient with Fabry disease.
Consider how the first and only oral therapy may help
For adults with confirmed Fabry disease and an amenable galactosidase alpha gene (GLA) variant associated with either the classic* or non-classic phenotype1,2
*
Defined as males with residual peripheral blood mononuclear cell alpha-galactosidase A (alpha-Gal A)
INDICATIONS AND USAGE
Galafold® (migalastat) is indicated for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data.
This indication is approved under accelerated approval based on reduction in kidney interstitial capillary cell globotriaosylceramide (KIC GL-3) substrate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
AMICUS ASSIST is a program designed to provide assistance and support to help eligible patients with Fabry disease and an amenable GLA variant obtain access to Galafold.*
*Patients must be prescribed Galafold for an approved indication to be eligible for support from AMICUS ASSIST.
This form serves a dual purpose: as a prescription for Galafold and as a way for patients to register for AMICUS ASSIST.
Learn about a no-charge option for genetic testing to help you confirm a diagnosis and determine your patient’s specific GLA variant.